<div id="readability-page-1"><p>CenterBook Partners LP cut its stake in shares of  Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor  owned 283,627 shares of the company's stock after selling 3,146,628 shares during the period. CenterBook Partners LP owned approximately 0.18% of Humacyte worth $494,000 at the end of the most recent reporting period.</p><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of HUMA. CWM LLC boosted its stake in shares of  Humacyte by 29,921.4% in the second quarter. CWM LLC now owns 43,531 shares of the company's stock valued at $91,000 after purchasing an additional 43,386 shares during the period.  Savant Capital LLC acquired a new position in  Humacyte in the 2nd quarter worth $122,000.  Vanguard Personalized Indexing Management LLC purchased a new position in  Humacyte in the 2nd quarter valued at about $30,000.  SBI Securities Co. Ltd. grew its stake in shares of  Humacyte by 6,305.4% during the second quarter. SBI Securities Co. Ltd. now owns 68,218 shares of the company's stock valued at $143,000 after acquiring an additional 67,153 shares in the last quarter.  Finally, Letko Brosseau &amp; Associates Inc. increased its position in shares of  Humacyte by 85.3% during the second quarter. Letko Brosseau &amp; Associates Inc. now owns 45,950 shares of the company's stock worth $96,000 after acquiring an additional 21,150 shares during the last quarter. Hedge funds and other institutional investors own  44.71% of the company's stock. </p><h2>Humacyte Stock Down 1.7%</h2><p>Shares of NASDAQ:HUMA opened at $1.13 on Friday. The company's fifty day moving average is $1.06 and its two-hundred day moving average is $1.39. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte, Inc. has a 1-year low of $0.88 and a 1-year high of $3.94. The stock has a market capitalization of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93. </p><h2>Analyst Upgrades and Downgrades</h2><p>HUMA has been the subject of a number of analyst reports. D. Boral Capital  restated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday. Benchmark reduced their target price on Humacyte from $11.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, January 21st. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Humacyte in a research report on Monday, December 29th. Wall Street Zen cut shares of Humacyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, December 21st. Finally, BTIG Research  reiterated a &#34;buy&#34; rating and set a $6.00 price objective on shares of Humacyte in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.14.</p><p><b>Read Our Latest Report on HUMA</b></p><h2>Humacyte Profile</h2> (Free Report)<p>Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.  </p><p>The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Humacyte</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>Gold $5,000: The 2026 Gold &amp; Silver Summit is LIVE March 4</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>This makes me furious</li><li>Elon Musk: This Could Turn $100 into $100,000</li></ul><p><strong>Want to see what other hedge funds are holding HUMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Humacyte Right Now?</h2><p>Before you consider Humacyte, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p><p>While Humacyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

HUMA

SBIO

<p>CenterBook Partners LP significantly reduced its stake in Humacyte, Inc. (NASDAQ:HUMA) by 91.7% in Q3, now holding 283,627 shares after selling 3,146,628 shares. Other institutional investors have also adjusted their positions. Humacyte's stock is currently down 1.7%, trading at $1.13, with a market cap of $211.62 million. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $8.14. Humacyte focuses on developing regenerative human acellular vessels for vascular access needs.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Humacyte

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP